Bli medlem
Bli medlem

Du är här


Nanexa: Redeye initiates coverage of Nanexa

Redeye initiates coverage of Nanexa, an early-stage drug delivery
company able to enhance compounds already on the market. Our
confidence in management's ability to commercialise its technology
platform underpins our positive stance, while the share's undemanding
valuation after a recent capital raise provides an attractive entry

Read more and download the Research Update:

Start following companies at Redeye to receive the latest equity
research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment


Författare Cision News

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.